Patent licensing beats a defensive portfolio once licensing revenue can run at least 10 times what a company spends on patents, know-how, and trade secrets, the 10:1+ rule. This applies almost by default in semiconductors, telecoms, and increasingly biotech, where no single company owns its full production stack. Below that ratio, a defensive strategy budgeted at 1–2% of investment or revenue is the better fit.
Most advice on patent strategy assumes you're building a portfolio to defend your own product. But for a meaningful slice of deep tech, semiconductors, telecoms, parts of biotech, that assumption is wrong from day one. If you can't realistically own your entire supply chain, defense isn't your strategy. Patent licensing is.
Here's how to tell which camp you're in, and what changes once you know.
The mindset shift: patents protect the business, not the technology
Before the licensing question, one reframe has to land: a patent's job isn't to protect your technology. It's to protect your business.
Technology without revenue or investment behind it is unprotected, no matter how many patents sit on top of it. A patent with no business underneath it is a plaque on the wall — nice to look at, useless to the company. What you're actually protecting is investor capital, future revenue, and, most concretely, your margins and pricing power. As long as you hold a patent monopoly on a product, you can hold 50%, 60%, 70% margins. The moment a competitor builds a lookalike, margins compress fast, regardless of how much worse their version is.
That reframe is what decides everything downstream, including which of the two patent strategies actually fits your business.
Two strategies, one fork in the road
There are two base patent strategies, and they lead to almost opposite decisions about budget, coverage, and filing volume.
Defensive strategy protects your freedom to operate. You build a portfolio around a product you intend to own and sell yourself, budgeted at roughly 1–2% of investment or projected revenue — treated as business insurance, not an R&D expense. We've covered the defensive playbook and the funding-stage buildout (checkbox patent → seed → Series A) in detail in our patent strategy guide for growing tech companies.
Licensing strategy is what you reach for when owning the entire product isn't realistic. Two industries default to this almost immediately: telecommunications and semiconductors, where production lines are too expensive and too complex for any one company to own the full stack. In those fields, you're rarely selling a finished product. You're selling a piece of the puzzle, and increasingly, the same logic is showing up in biotech and life sciences, where the supply chain has gotten too complex for any single company to control end to end.
The rest of this piece is about that second path, because it runs on completely different math.
The 10:1+ rule: patents are your product
If you're licensing, your patents aren't protecting a product. They are the product, combined with know-how and, often, trade secrets and source code.
The rule of thumb: target at least 10x (preferably more) the revenue you generate compared to what you spend on patents, know-how, and trade secrets. That ratio is the whole business model. Your growth scales directly with how many strong patents you can file, which is why licensing-first companies, especially in semiconductors, spend heavily and file constantly. The spend isn't overhead. It's the product line.
This is also why "we don't have enough ideas to patent" doesn't hold up as a reason to slow down. Patent idea supply is essentially never the real constraint, you can file on an improvement that's 1% better than what you shipped last year, and if you're actively developing technology, that supply doesn't run out. The actual constraint is always budget, not ideas. (The one exception: companies with functionally unlimited budgets, who really can file on everything. Everyone else is choosing.)
Why licensing needs heavier coverage than defense
Licensing means telling someone else how to do something, which is a fundamentally more exposed position than simply using your own technology quietly in-house. Once you're licensing, competitors and licensees alike have a much clearer view into where the gaps in your portfolio might be. That raises the bar on coverage: you need more filings, spread more deliberately, to close the holes a defensive-only company could get away with leaving open.
One rule holds regardless of which strategy you're running: never patent your secret sauce. If a competitor can't reverse-engineer it without your source code or your manufacturing line, filing on it just gives away information for no defensive gain. Decide, product by product, what's worth disclosing in a patent and what belongs in a trade secret instead.
You rarely have to pick just one
Defensive and licensing aren't a binary choice for the whole company, they're a spectrum, and most growing tech companies end up somewhere in the middle, often split by product line or by market.
A common pattern: your core, high-margin product in markets you can fully control (typically Western markets where you can own distribution end to end) stays defensive. Meanwhile, product lines headed into markets where you need a local partner, Korea, Japan, other parts of Asia are common examples for Western companies, often shift toward licensing, because a partner is close to unavoidable there. Geography plays into strategy here as much as product does; if international markets are part of your roadmap, our guide to international patent filing covers how filing decisions change once you cross borders.
The decision isn't "are we a licensing company or a defensive company." It's "which strategy fits this product, in this market, at this stage", and that answer can, and should, be different across your own portfolio.
Defensive vs licensing, at a glance
- Goal — Defensive: freedom to operate, stop copying; Licensing: revenue from IP itself
- Typical spend — Defensive: 1–2% of investment/revenue; Licensing: target 10x+ revenue vs. patent + know-how spend
- Common industries — Defensive: products you build and sell yourself; Licensing: semiconductors, telecoms, complex biotech supply chains
- Coverage needs — Defensive: enough to block copying; Licensing: heavy, you're exposing more by design
- Portfolio size signals — Defensive: coverage and freedom to operate; Licensing: company value and deterrence
What this means for your portfolio, practically
If you're building defensively, the goal is coverage: no gaps a competitor can walk through, filings spread across your product rather than stacked on one feature, and a strategy you can explain clearly to investors and your own team even when the portfolio is still small.
If you're leaning into licensing, the goal is volume with discipline: filing consistently against the 10:1+ target, treating patent spend as a growth investment rather than a cost center, and getting your CFO involved early, since this is where a meaningful share of company value ends up sitting by the time you're raising a Series A or later.
Either way, the question to keep asking isn't "how many patents do we have." It's "does our patent strategy match how we actually make money" — because a defensive budget applied to a licensing business starves the thing that's supposed to be growing, and a licensing-level spend applied to a pure defensive business burns cash you need elsewhere.
FAQ
What is patent licensing as a business strategy? It's a patent strategy built around generating revenue from your IP, combined with know-how and often trade secrets, rather than exclusively protecting a product you manufacture and sell yourself. It's most common in industries like semiconductors and telecommunications, where owning the full production stack isn't realistic.
How much should a company spend on patents if it's pursuing a licensing strategy? A useful target is the 10:1+ rule: aim for at least 10 times more revenue than what you spend on patents, know-how, and trade secrets combined. This differs sharply from a defensive strategy, which typically runs at 1–2% of investment or projected revenue.
Can a startup run both a defensive and a licensing strategy at the same time? Yes, and many growing tech companies do, often split by product line or by target market. A high-margin product in a market you fully control might stay defensive, while a product entering a market that requires a local partner may shift toward licensing.
Does patent licensing require more patents than a defensive strategy? Generally, yes. Licensing means disclosing more about how your technology works, which increases the risk of competitors finding gaps. That calls for heavier, more deliberate coverage than a defense-only portfolio typically needs.
Will a startup run out of patentable ideas? In practice, no. Patent idea supply is rarely the real constraint, even a 1% improvement over last year's version can be patentable. Budget, not idea supply, is almost always the limiting factor.
Not sure whether your product mix points toward defensive, licensing, or a split? Get a free patent strategy session and we'll map it out with you.
Watch more in my webinar, Patent Strategy for Growing Tech Companies, where I walk through this alongside the full defensive playbook.
.webp)